Diabetes Care · 2004 · 182 citations · 21 references
MedicineEndocrinologyInternal MedicineDiabetologyRenal PathologyRenal PathophysiologyDiabetes MellitusDiabetic Kidney DiseaseDiabetic NephropathyInsulin ResistanceRenal DiseaseRenal ImpairmentDiabetes-associated Cardiac RiskDiabetes-related ComplicationsDiabetic Cardiovascular PathologyMacrovascular ComplicationsSerum Creatinine AssessmentVascular Endothelial Dysfunction
OBJECTIVE: Increased plasma concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, has been associated with endothelial dysfunction, insulin resistance, and atherosclerosis in nondiabetic populations. In end-stage renal failure, circulating ADMA is elevated and a strong predictor of cardiovascular outcome. This study investigated the relation between ADMA and diabetic micro- and macrovascular complications in a large cohort of type 1 diabetic patients with and without early diabetic nephropathy. RESEARCH DESIGN AND METHODS: ADMA concentrations in plasma were determined by a high-performance liquid chromatography method in 408 type 1 diabetic patients with overt diabetic nephropathy (252 men; mean age 42.7 years [SD 11.0], mean duration of diabetes 28 years [SD 9], median serum creatinine level 102 micromol/l [range 52-684]). A group of 192 patients with longstanding type 1 diabetes and persistent normoalbuminuria served as control subjects (118 men; mean age 42.6 years [SD 10.2], mean duration of diabetes 27 years [SD 9]). RESULTS: In patients with diabetic nephropathy, mean +/- SD plasma ADMA concentration was elevated 0.46 +/- 0.08 vs. 0.40 +/- 0.08 micromol/l in normoalbuminuric patients (P<0.001). An increase in plasma ADMA of 0.1 micromol/l increased the odds ratio of nephropathy to 2.77 (95% CI 1.89-4.05) (P<0.001). Circulating ADMA increased in nephropathy patients with declining kidney function, as indicated by elevated values in the lower quartiles of glomerular filtration rate (<76 ml.min(-1).1.73 m(-2)) (P<0.001 ANOVA). Mean ADMA levels were similar in patients with or without diabetic retinopathy (P>0.2). However, in 44 patients with nephropathy and history of myocardial infarction and/or stroke, ADMA was significantly elevated at 0.48 +/- 0.08 micromol/l compared with 0.46 +/- 0.08 micromol/l in patients without major cardiovascular events (P=0.05). CONCLUSIONS: Elevated circulating ADMA may contribute to the excess cardiovascular morbidity and mortality in early diabetic nephropathy.
21
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
A. Leone, S. Moncada, Patrick Vallance et al. · The Lancet · 1992 · 2.1K citations
Medicine, Nephrology, Pharmacology +11
Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus
Ken Y. Lin, Akira Ito, Tomoko Asagami et al. · Circulation · 2002 · 658 citations